35 results about "Chimpanzee adenovirus" patented technology

The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

The invention relates to an expression vector based on an adenovirus AdC68 and a construction method thereof. By improving a construction method, the vaccine vector based on a chimpanzee adenovirus AdC68 genome is constructed. The vaccine vector can be applied to preparation of a vaccine capable of high-efficiency expression and having good immunogenicity.

The invention relates to an expression vector based on adenovirus AdC7 and its construction method. An effective strategy is designed for successfully construct the new expression vector based on chimpanzee adenovirus AdC7. The vaccine vector can be applied to the preparation of high expression viral vaccines with good immunogenicity.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).

The invention relates to a chimpanzee adenovirus vector based Ebola virus vaccine. The chimpanzee adenovirus vector based Ebola virus vaccine is characterized in that replication-defective chimpanzeeadenovirus vector is utilized to build a novel Ebola virus vaccine. The vaccine vector is applicable to preparation of a virus vaccine with efficient expression and high immunogenicity. The Ebola virus vaccine is simple to prepare, low in cost, high in safe, and free from additives.

The invention provides a respiratory syncytial virus full-length pre-fusion glycoprotein nucleotide sequence, a recombinant adenovirus vector and an application product thereof. The full-length pre-fusion glycoprotein nucleotide sequence comprises four mutation loci including S155C, S190F, V207L and S290C, a transmembrane region and an intracellular region of fusion glycoprotein are reserved, anda sequence table of the full-length pre-fusion glycoprotein nucleotide sequence is shown as a sequence 1. The invention further provides a chimpanzee replication-defective recombinant adenovirus vector pChAd63 or a human replication-defective recombinant adenovirus vector pAd26 containing the full-length pre-fusion glycoprotein nucleotide sequence, an initial strain of the adenovirus vector is chimpanzee adenovirus 63 type or human adenovirus 26 type, adenovirus E1 and E3 regions are deleted, and E4orf6 is replaced with human 5-type adenovirus E4orf6. The invention further provides a product applying the recombinant adenovirus. After the recombinant adenovirus vector is used for immunizing animals, the bodies can be induced to generate strong cellular immunity and humoral immunity reactions in a short time, and the generated antibody has high recognition capability on pre-fusion F and has a good immune effect and an immune protection effect.

There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

The present invention relates to a new rabies vaccine and method for preparation thereof. The present inventor has constructed, on the basis of a vaccine vector of the genome of chimpanzee adenovirus AdC68, a new type of rabies vaccine vector. The present invention also provides a viral vaccine prepared using said vaccine vector, highly expressed, and having good immunogenicity.

There is provided a method of treating chronic hepatitis B infection (CHB) and / or chronic hepatitis D infection (CHD) in a human, comprising the steps of: a) administering to the human a composition comprising an antisense oligonucleotide (ASO) 10 to 30 nucleosides in length, targeted to a HBV nucleic acid (an HBV ASO); b) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); c) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and d) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human acomposition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

Chimpanzee adenovirus (ChAd) and MVA virus vectors containing polynucleotide sequences encoding cancer antigens are administered sequentially to a subject in a suitable adjuvant in order to achieve a prime boost effect. The polynucleotides are expressed in situ following administration to provide a MAGEA3 / linker / NY-ESO-1 fusion protein and variants thereof. Also, a hli / MAGEA3 / linker / NY-ESO-1 fusion protein and variants thereof. An improved T cell response is found. In a particular synergistic therapeutic approach a triple combination of ChAdOx and MVA vectors together with chemotherapeutic agent and checkpoint inhibitor results in depleted myeloid derived suppressor cells (MDSC) and dramatically improves survival time in a mouse model of cancer.

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

The invention relates to an expression vector based on adenovirus AdC7 and its construction method. An effective strategy is designed for successfully construct the new expression vector based on chimpanzee adenovirus AdC7. The vaccine vector can be applied to the preparation of high expression viral vaccines with good immunogenicity.

Disclosed are a chimpanzee adenovirus vector-based zika virus vaccine and a preparation method therefor, belonging to the fields of biotechnology and virology. A chimpanzee adenovirus AdC7 is constructed as a replication defective recombinant expression vector. The vector has good immunogenicity and genetic stability, and a novel zika virus vaccine is prepared on the basis of the vector. Neutralizing antibodies against zika virus are effectively induced in mice which have been immunised with the vaccine, thereby protecting the mice from being infected, and also protecting the tissues and organs of the mice from being damaged.

The invention discloses a recombinant chimpanzee adenovirus for expressing rabies virus G protein and a preparation method of the recombinant chimpanzee adenovirus, and relates to the technical field of biology. The adenovirus comprises a Gp gene after codon optimization, a WPRE after transcription regulation element and an AdC68 genome sequence containing KE, AK, XA and PX fragments, and a connecting sequence is inserted between the 594th site and the 3513th site in the AdC68 genome to replace a part of E1 sequence between the 459th site and the 3011th site. The codon of the Gp gene is optimized, and a WPRE transcriptional regulatory element is inserted, so that the high-level secretory expression of the rabies virus G protein is realized. The structure and function of the obtained rabies virus G protein are completely consistent with those of a natural state, the immunogenicity of the G protein is reserved to the maximum extent, and the G protein can be better recognized by antigen presenting cells. And the prepared rabies vaccine also has high immunogenicity, low prestored antibody property and safety.